Vaccination of BALB/c Mice withEscherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge

• DOI: 10.1128/jvi.01854-07
• Publication Date: 2008-01-17T01:33:48Z
• Authors: Aklile Berhanu; Rebecca L. Wilson; Dana L. Kirkwood-...; David S. King; Travis K. Warren; Susan A. Lund; Lindsay L. Brown; Alex K. Krupkin; Erin VanderMay; Will Weimers; Kady M. Honeychurch; Douglas W. Grosen...; Kevin F. Jones; Dennis E. Hruby
• Keywords: Orthopoxvirus; Poxviridae; Smallpox vaccine

The potential threat of smallpox use in a bioterrorist attack has heightened the need to develop an effective vaccine for immunization general public. Vaccination with current vaccine, Dryvax, produces protective immunity but may result adverse reactions some vaccinees. A subunit composed vaccinia virus proteins should avoid complications arising from live-virus vaccination and thus provide safer alternative vaccine. In this study, we assessed efficacy immunogenicity multisubunit A27L D8L intracellular mature (IMV) form B5R protein extracellular enveloped (EEV) virus. BALB/c mice were immunized Escherichia coli-produced A27L, D8L, adjuvant consisting monophosphoryl lipid trehalose dicorynomycolate or TiterMax Gold adjuvant. Following immunization, either sacrificed analysis immune responses lethally challenged by intranasal inoculation strain Western Reserve. We observed that three immunizations alone induced potent neutralizing antibody provided complete protection against lethal challenge. Several linear B-cell epitopes within recognized sera mice. addition, protein-specific cellular detected spleens gamma interferon enzyme-linked immunospot assay using peptides derived each protein. Our data suggest incorporating bacterially expressed IMV- EEV-specific can be stimulating anti-vaccinia providing